[Combination chemotherapy with docetaxel and cisplatin in patients with hormone-refractory prostate cancer].
We investigated the efficacy of docetaxel and cisplatin for hormone-refractory prostate cancer (HRPC). Thirteen patients with HRPC were treated with 30 mg/m2 docetaxel weekly for 3 weeks and 70 mg/m2 cisplatin on day 1. Treatment was repeated every 21 days. They received 2 cycles and were evaluated for the responses to serum prostate-specific antigen (PSA) and tumor size. Ten (77%) of the 13 patients showed a 50% or greater decrease in PSA with a median time to progression of 3 months. One of the 2 patients with measurable soft tissue disease showed a reduction in disease. No severe toxicity of this regimen was observed. Combination chemotherapy with docetaxel and cisplatin in patients with HRPC was well tolerated and efficatious with a significant decrease in serum PSA and measurable disease.
Fujinami
Kiyoshi
K
The Department of Urology, Kanagawa Cancer Center.
Miura
Takeshi
T
Takizawa
Akitoshi
A
Osada
Yutaka
Y
D000368:Aged; D000726:Androgen Antagonists / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D004054:Diethylstilbestrol / Q000031:analogs & derivatives* / Q000494:pharmacology; D000077143:Docetaxel; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D043823:Taxoids / Q000008:administration & dosage
D000726:Androgen Antagonists; D043823:Taxoids; D000077143:Docetaxel; D004054:Diethylstilbestrol; D017430:Prostate-Specific Antigen; D002945:Cisplatin; C000937:diethylstilbestrol dipropionate